EXPAREL Patent Fight: Pacira vs. WhiteOak

Patent war brewing! Pacira BioSciences faces a major challenge as WhiteOak Group seeks to create a generic version of their blockbuster non-opioid pain relief drug, EXPAREL. With nineteen patents at stake and billions of dollars on the line, Pacira is gearing up for a legal fight that could reshape the future of pain management. Will Pacira defend its turf, or will a new competitor emerge?The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.